Hangzhou Tigermed Consulting Co., Ltd (HNGZY)

OTCMKTS · Delayed Price · Currency is USD
4.000
0.00 (0.00%)
May 11, 2026, 4:00 PM EST
Market Cap5.86B +19.7%
Revenue (ttm)1.03B +8.7%
Net Income111.85M +129.9%
EPS0.13 +135.5%
Shares Outn/a
PE Ratio52.37
Forward PE32.53
Dividend0.03 (0.72%)
Ex-Dividend DateJun 13, 2025
Volume612
Average Volume454
Open4.000
Previous Close4.000
Day's Range4.000 - 4.000
52-Week Range4.000 - 4.300
Beta0.62
RSIn/a
Earnings DateApr 29, 2026

About HNGZY

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, includ... [Read more]

Sector Healthcare
Founded 2004
Employees 11,130
Stock Exchange OTCMKTS
Ticker Symbol HNGZY

Financial Performance

In 2025, HNGZY's revenue was 6.83 billion, an increase of 3.48% compared to the previous year's 6.60 billion. Earnings were 887.89 million, an increase of 119.15%.

Financial numbers in CNY Financial Statements